KR101656536B1 - 페오니플로린 제제 및 지방 감소를 위한 그의 용도 - Google Patents

페오니플로린 제제 및 지방 감소를 위한 그의 용도 Download PDF

Info

Publication number
KR101656536B1
KR101656536B1 KR1020107029010A KR20107029010A KR101656536B1 KR 101656536 B1 KR101656536 B1 KR 101656536B1 KR 1020107029010 A KR1020107029010 A KR 1020107029010A KR 20107029010 A KR20107029010 A KR 20107029010A KR 101656536 B1 KR101656536 B1 KR 101656536B1
Authority
KR
South Korea
Prior art keywords
fat
amount
adipocytes
expression
formulation
Prior art date
Application number
KR1020107029010A
Other languages
English (en)
Korean (ko)
Other versions
KR20110138322A (ko
Inventor
바크르 라비
Original Assignee
바크르 라비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바크르 라비 filed Critical 바크르 라비
Publication of KR20110138322A publication Critical patent/KR20110138322A/ko
Application granted granted Critical
Publication of KR101656536B1 publication Critical patent/KR101656536B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0452—Specially adapted for transcutaneous muscle stimulation [TMS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0004—Applications of ultrasound therapy
    • A61N2007/0008—Destruction of fat cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Electrotherapy Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
KR1020107029010A 2008-05-23 2009-05-25 페오니플로린 제제 및 지방 감소를 위한 그의 용도 KR101656536B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/126,246 2008-05-23
US12/126,246 US7943187B2 (en) 2008-05-23 2008-05-23 Paeoniflorin preparations and uses thereof for fat reduction

Publications (2)

Publication Number Publication Date
KR20110138322A KR20110138322A (ko) 2011-12-27
KR101656536B1 true KR101656536B1 (ko) 2016-09-12

Family

ID=41342622

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107029010A KR101656536B1 (ko) 2008-05-23 2009-05-25 페오니플로린 제제 및 지방 감소를 위한 그의 용도

Country Status (10)

Country Link
US (4) US7943187B2 (fr)
EP (1) EP2300018B1 (fr)
JP (1) JP5507549B2 (fr)
KR (1) KR101656536B1 (fr)
CN (1) CN102170888B (fr)
AU (2) AU2009345773A1 (fr)
CA (1) CA2725972A1 (fr)
DK (1) DK2300018T3 (fr)
HK (1) HK1159477A1 (fr)
WO (1) WO2010127470A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
WO2011117869A1 (fr) * 2010-03-23 2011-09-29 Real Aesthetics Ltd. Système et procédé pour accélérer la proportion relative de catabolisme des graisses
AU2014340351B2 (en) 2013-10-21 2020-01-30 Alevere Medical Corporation Fused heterocyclic organic compounds, pharmaceutical compositions, and medical uses thereof
JP2018532806A (ja) * 2015-11-04 2018-11-08 キセラ バイオファーマシューティカルズ インコーポレイテッド デオキシコール酸およびその塩による蓄積脂肪の処置方法
EP3750546A4 (fr) 2018-02-09 2021-10-27 Kohaku Bio Technology Co., Ltd. Promoteur de libération de glycérol
KR102392292B1 (ko) 2021-07-21 2022-05-03 중앙대학교 산학협력단 페오니플로린을 포함하는 악액질 및 근손실 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6485990A (en) * 1987-09-28 1989-03-30 Tsumura & Co Antihypertestoeronemia agent
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US5919621A (en) * 1991-10-24 1999-07-06 Brown; David B. Methods for diagnosing human male infertility
IL101387A (en) * 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US5480772A (en) * 1993-02-03 1996-01-02 Brandeis University In vitro activation of a nucleus
FR2717382B1 (fr) 1994-03-21 1996-06-07 Fabre Pierre Cosmetique Extraits de Paeonia Lactiflora titré en paeoniflorine utiles en cosmétologie dans le traitement capillaire.
PE17897A1 (es) * 1995-02-17 1997-06-12 Lilly Co Eli Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
US5698199A (en) * 1995-03-10 1997-12-16 Kao Corporation Lipolysis acceleration method
AU9627898A (en) 1997-10-08 1999-04-27 S.W. Patentsverwertungs Gesellschaft M.B.H. Tightening and/or reducing the size of body parts containing fat cells
US6638064B1 (en) * 2000-06-07 2003-10-28 Robert Scott Nance Flexible endodontic syringe
US7963935B2 (en) * 2001-04-20 2011-06-21 Alza Corporation Microprojection array having a beneficial agent containing coating
CN2560367Y (zh) * 2001-08-30 2003-07-16 夏勤 适于喉部和气管滴入药物的针头
US20030175328A1 (en) * 2002-03-06 2003-09-18 Adi Shefer Patch for the controlled delivery of cosmetic, dermatological, and pharmaceutical active ingredients into the skin
JP2004217583A (ja) * 2003-01-16 2004-08-05 Naris Cosmetics Co Ltd 痩身用皮膚外用剤
US20040191330A1 (en) * 2003-03-31 2004-09-30 Keefe Candace R. Daily skin care regimen
CN1555806A (zh) * 2003-12-31 2004-12-22 昆明同持医药研究有限公司 一种芍药甙注射剂及其制备方法和应用
KR20050107649A (ko) * 2004-05-10 2005-11-15 주식회사 엘지생활건강 페오니플로린을 포함하는 피부 노화 억제용 조성물
KR100769580B1 (ko) * 2005-03-07 2007-10-23 주식회사 엘지생활건강 자외선에 의한 피부 ｄｎａ 손상 방지제
CH697417B1 (de) 2004-05-10 2008-09-30 Lg Household & Health Care Ltd Mittel zur Behandlung der Hautalterung enthaltend Paeoniflorin.
MXPA06013437A (es) 2004-05-19 2007-03-23 Los Angeles Biomed Res Inst Uso de un detergente para la eliminacion no quirurgica de grasa.
US7530958B2 (en) * 2004-09-24 2009-05-12 Guided Therapy Systems, Inc. Method and system for combined ultrasound treatment
JP4974533B2 (ja) * 2006-01-30 2012-07-11 富士フイルム株式会社 ジスルフィド架橋したタンパク質ナノ粒子
US20080294072A1 (en) * 2007-05-24 2008-11-27 Crutchfield Dermatology Mesotherapy with ultrasound
US7943187B2 (en) * 2008-05-23 2011-05-17 Bakr Rabie Paeoniflorin preparations and uses thereof for fat reduction

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Fitoterapia. 2004. Vol.75, pp.45-49.*
International Journal of Pharmaceutics. 2003. Vol.257, pp.169-180.*

Also Published As

Publication number Publication date
DK2300018T3 (en) 2017-09-11
WO2010127470A1 (fr) 2010-11-11
EP2300018A4 (fr) 2011-07-20
US7943187B2 (en) 2011-05-17
US20090292238A1 (en) 2009-11-26
US20170216333A1 (en) 2017-08-03
US8491947B2 (en) 2013-07-23
US20150018906A1 (en) 2015-01-15
EP2300018B1 (fr) 2017-05-17
HK1159477A1 (en) 2012-08-03
US20110218163A1 (en) 2011-09-08
JP2011523950A (ja) 2011-08-25
JP5507549B2 (ja) 2014-05-28
US9901591B2 (en) 2018-02-27
CA2725972A1 (fr) 2010-11-11
US20170368086A9 (en) 2017-12-28
EP2300018A1 (fr) 2011-03-30
CN102170888A (zh) 2011-08-31
KR20110138322A (ko) 2011-12-27
AU2015242976A1 (en) 2015-11-05
CN102170888B (zh) 2013-06-19
AU2009345773A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
KR101656536B1 (ko) 페오니플로린 제제 및 지방 감소를 위한 그의 용도
CA2827643C (fr) Traitement de graisse sous-mentale
KR20070054222A (ko) 진통 작용이 있는 약제 조성물
TW201803561A (zh) 軟性抗膽鹼類似物之製劑
MX2014004362A (es) Preparado de huevo con propiedades regeneradoras, analgesicas y/o anti-inflamatorias.
CN114028416B (zh) 一种用于治疗化疗诱发的外周神经病变的组合物及其应用
KR20080097420A (ko) 티오우레아 유도체를 함유하는 소양성 또는 자극성피부질환의 예방 또는 치료용 외용제 조성물
CN117338889B (zh) 防治血瘀证的精油组合物及其用途
KR102230271B1 (ko) 지방감소를 위한 글라이코데옥시콜릭산 (Glycodeoxycholic acid, GDCA)를 유효성분으로 포함하는 주사용 제제 및 조성물
US20180055848A1 (en) Combination of Albuterol and Caffeine as Synergistic Treatment for Obesity or Sarcopenia
Greenway et al. Anthropometry of local fat reduction
Barbosa et al. Body Harmonization: The Definition of a New Concept
Raffa Analgesic patent applications: I
CN110420209A (zh) 一种治疗糖尿病周围神经痛的药物组合物及其应用
CN102988338A (zh) 硝酸酯及其对肌肉和肌肉相关疾病的治疗用途
US20070042998A1 (en) Medical cosmetic method for reducing adipose tissue and for initiating lipolysis through subcutaneous and intracutaneous injections and customized composition compounded from pharmaceutical agents for use therein
Beilin Body mesotherapy and ‘mesobotox’
BERBECE et al. Use of Phosphatidylcholine in the Treatment of Localized Fat Deposits
GALLATE MEDICINAL ACTION AND INTERACTION OF ANDROGENS
CN104940193A (zh) 一种含辛伐他汀的降血脂血糖药物组合物及其应用

Legal Events

Date Code Title Description
N231 Notification of change of applicant
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant